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Background: Fetal alcohol spectrum disorder (FASD) is known to be under-recognised in Australia. The use of
standard methods to identify when to refer individuals who may have FASD for specialist assessment could help
improve the identification of this disorder. The purpose of this study was to develop referral criteria for use in
Australia.
Method: An online survey about FASD screening and diagnosis in Australia, which included 23 statements
describing criteria for referral for fetal alcohol syndrome (FAS) and FASD based on published recommendations for
referral in North America, was sent to 139 health professionals who had expertise or involvement in FASD screening
or diagnosis. Survey findings and published criteria for referral were subsequently reviewed by a panel of 14
investigators at a consensus development workshop where criteria for referral were developed.
Results: Among the 139 health professionals who were sent the survey, 103 (74%) responded, and 90 (65%)
responded to the statements on criteria for referral. Over 80% of respondents agreed that referral for specialist
evaluation should occur when there is evidence of significant prenatal alcohol exposure, defined as 7 or more
standard drinks per week and at least 3 standard drinks on any one day, and more than 70% agreed with 13 of the
16 statements that described criteria for referral other than prenatal alcohol exposure. Workshop participants
recommended five independent criteria for referral: confirmed significant prenatal alcohol exposure; microcephaly
and confirmed prenatal alcohol exposure; 2 or more significant central nervous system (CNS) abnormalities and
confirmed prenatal alcohol exposure; 3 characteristic FAS facial anomalies; and 1 characteristic FAS facial anomaly,
growth deficit and 1 or more CNS abnormalities.
Conclusion: Referral criteria recommended for use in Australia are similar to those recommended in North America.
There is a need to develop resources to raise awareness of these criteria among health professionals and evaluate
their feasibility, acceptability and capacity to improve the identification of FASD in Australia.
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There are known limitations in the recognition and
diagnosis of fetal alcohol spectrum disorder (FASD) in
Australia and elsewhere, with the diagnosis of FASD
often delayed or missed [1]. Estimates of the prevalence
of fetal alcohol syndrome (FAS) in Australia (0.6 - 0.7
per 1000 live births [2-4]), are low compared with inter-
national estimates. The prevalence of FAS in the United
States is estimated to be at least 2–7 per 1000 popula-
tion, and the prevalence of FASD among school children
in the United States and some Western European coun-
tries is estimated to be as high as 2-5% [5]. High risk
population subgroups have also been identified, includ-
ing Indigenous populations and those in correctional
and out of home care settings [3,6-8].
The varied nature of FASD presentations with respect
to both dysmorphology and neuropsychological profile,
and the lack of valid and reliable screening tests likely
contribute to poor awareness of FASD as a possible differ-
ential diagnosis, uncertainty about the need for specialist
assessment, infrequent referral for specialist assessment,
and underidentification of this disorder. Strategies to in-
crease recognition and diagnosis include training to im-
prove awareness of FASD among health professionals
[9,10] and establishment of dedicated clinical services
for diagnosis and management [11]. However, the lack
of screening tools for FASD that are specific and sensi-
tive to prenatal alcohol exposure [12] contributes to
uncertainty and inconsistency in the methods used for
screening and referral [13].
Both the Canadian diagnostic guidelines for FASD
[12] and the United States Centers for Disease Control
and Prevention (CDC) diagnostic guidelines for FAS
[14] attempt to address these uncertainties through the
publication of criteria for referral. These criteria provide
guidance for health professionals on when to refer indi-
viduals with specific presentations suggestive of FAS or
FASD for specialist diagnostic evaluation. Criteria for
referral are intended to provide clinicians with guidance
relevant to routine clinical decision-making outside the
formal screening context, in the absence of suitable valid
and reliable formal screening tests.
There are similarities between the Canadian [12] and
CDC [14] criteria for referral. Both recommend referral
where there is confirmed significant prenatal alcohol
exposure, which is defined in the CDC guidelines as 7 or
more standard drinks per week, or 3 or more standard
drinks on multiple occasions [14]. In contrast, the lar-
gest interdisciplinary diagnostic program in Washington
State [15] uses any level of confirmed prenatal alcohol ex-
posure as the main criterion for acceptance into their
diagnostic assessment program. In lieu of information on
confirmed prenatal alcohol exposure, the presence of a full
FAS facial phenotype, which is highly specific to prenatalalcohol exposure [16-18], is also used as a criterion for
referral in the CDC guidelines, Canadian guidelines and
Washington State diagnostic program. The Canadian
guidelines also recommend referral in the presence of
probable significant prenatal alcohol exposure if at least
one characteristic FAS facial anomaly and an additional
diagnostic feature (growth deficit or central nervous sys-
tem abnormality) are present. In contrast, the CDC guide-
lines include additional criteria for referral that do not
require information on prenatal alcohol exposure, includ-
ing the presence of a facial anomaly and growth deficit or
central nervous system deficit, and parent or caregiver
concern that their child might have FAS.
There is no formal guidance for Australian health pro-
fessionals about when it is appropriate to refer individ-
uals for a specialist diagnostic assessment when FASD is
suspected. Surveys of paediatricians and other health
professionals indicate poor awareness of these condi-
tions and their diagnostic criteria, and a need for infor-
mation and resources to improve identification [10,19].
Australian health professionals have indicated their need
for standard guidelines and explicit criteria that identify
how to assess individuals who may have FASD and deter-
mine when a specialist diagnostic evaluation is required
[20]. This support for the development of standard criteria
for referral has been highlighted in recent consensus
recommendations for FASD screening and diagnosis in
Australia [21].
We have been unable to locate any formal evaluation of
published criteria for referral, although in the Washington
State program over 90% of referred individuals receive a
FASD diagnosis [15]. The lack of clear empirical evi-
dence to inform clinical decision-making in many areas
of health care has motivated researchers and policy
makers to use expert judgement and consensus to develop
clinical tools and practice guidelines [22-25]. Formal con-
sensus methods enable a wide range of knowledge and
experience to be considered in the criteria development
process, and provide a systematic approach to evaluate
and integrate multiple sources of evidence [26] and deal
with uncertainty [23]. Due to the lack of formal evidence
on the effectiveness of published referral criteria for FASD,
we aimed to develop consensus-based referral criteria to
facilitate appropriate referral practices and improved iden-
tification of FASD in Australia.
Methods
A consensus development workshop was used to review
evidence relevant to the development of locally appropriate
consensus criteria for referral. Two main sources of evi-
dence were considered: i) a published systematic review of
the literature on FASD screening and diagnosis [27], up-
dated to include literature published up to September
2010; and ii) findings from a survey of health professionals.
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A sample of 130 Australian and 9 international health
professionals was surveyed to evaluate agreement with
criteria for referral that were derived from published cri-
teria and identify perceptions relevant to the develop-
ment of criteria for referral in Australia. This survey was
conducted as part of a larger survey on the screening
and diagnosis of FASD in Australia, and survey methods
are reported in detail elsewhere [28].
Recruitment
Health professionals with expertise or experience in FASD
screening or diagnosis were invited to participate. Partici-
pants were recruited from three sources: medical practi-
tioners who had previously reported a case of FAS to the
Australian Paediatric Surveillance Unit (APSU) (n = 57)
[3]; health professionals who were identified by the study
investigators as having experience or expertise in FASD
screening or diagnosis, including international experts
in the field, based on the recommendation of consumer
and community participants (n = 128); and health profes-
sionals who responded to canvassing of health profes-
sional organisations calling for individuals with relevant
expertise (n = 35). Individuals passively enrolled via the
APSU were advised of the study prior to survey adminis-
tration, and were only removed from the panel if they de-
clined to participate (17/57). In contrast, participants who
were recruited via the steering group or professional orga-
nisations had all actively indicated their intention to par-
ticipate. Consistent with these differences in recruitment,
individuals who were passively recruited via the APSU
were less likely to respond to the survey (67.5%) compared
with participants who were recruited through professional
bodies (71.0%) or the study steering group (79.4%). Of the
220 individuals invited to participate in the survey, 81
either did not respond to the email invitation or declined
to participate prior to the survey administration and were
excluded from the study. The survey was administered to
139 individuals who agreed to participate in the study.
Survey development
Three published criteria for referral intended for use in
the general population were identified in the systematic
literature review. These included the Canadian guidelines
for the diagnosis of FASD [12,29], and the CDC guidelines
for the diagnosis of FAS [14], and referral criteria used by
the Washington State Fetal Alcohol Syndrome Diagnostic
and Prevention Network [15]. The main elements of these
published criteria for referral are summarised in Table 1.
We designed 23 statements to evaluate agreement with
a range of published criteria for referral (Table 2). Partici-
pants were asked to rate their agreement with each state-
ment on a 5-point Likert scale which ranged from ‘strongly
agree’ to ‘strongly disagree’. Participants were able to select‘no comment’ if they believed that a statement was outside
their area of expertise. Three open ended questions were
also used to elicit opinions on criteria for referral, includ-
ing the identification of alternative criteria. Pretesting was
performed with 16 clinicians and researchers to test the
online format and assess the clarity and face validity of the
survey.
Survey administration
The survey was administered online from a secure server.
An email containing a personal username and password
and a link to the survey website was sent to all partici-
pants. Participants were asked to respond within 14 days,
and email reminders were sent approximately 7 days and
2 days prior to the survey closure. When participant
telephone numbers were available, non-responders were
followed up by telephone and the survey closure date
extended to improve response.
Analysis
Descriptive statistics were generated for each statement,
including response frequencies, median scores and inter-
quartile deviation (IQD). Consensus agreement was de-
fined a priori as 70% agreement. Qualitative data were
independently coded and analysed by two investigators
using qualitative inductive content analysis methods
[30,31]. Data from each open ended question were
reviewed alongside the quantitative data and coded in-
ductively based on the underlying meaning of the re-
sponses. Both analysts’ coding schemes were reviewed
for consistency to ensure the credibility and trustworthi-
ness of the analysis process [30].
Consensus development workshop
A consensus development workshop was held to develop
recommendations for FASD screening, referral and diag-
nosis in Australia. Workshop methods and general rec-
ommendations, including criteria for diagnosis, are
described in detail elsewhere [21].
Participants
A panel of investigators with expertise in FASD was
formed to conduct the study, review the findings of the
systematic review and health professional survey, and
develop consensus criteria for referral in Australia. Panel
members included paediatricians and other health pro-
fessionals, health researchers and consumer and com-
munity representatives, and three of the panel members
were Indigenous. Panel members met monthly by tele-
conference prior to the face-to-face workshop to provide
input on study design, and to review and oversee the
collection and evaluation of evidence to be considered in
recommendation development. Only 13 of the 17 panel
members were able to attend the 2-day workshop at
Table 1 Summary of published criteria for referral for individuals who may have fetal alcohol syndrome or fetal
alcohol spectrum disorder by criteria content*
Criterion main content Chudley [12] Loock [29] CDC [14] Astley [15]
1. Any confirmed prenatal alcohol exposure (PAE) - - - Yes
2. Confirmed significant PAE† Yes Yes Yes -
3. 3 characteristic FAS facial anomalies‡ Yes - Yes Yes
4. PAE (significant) and 3 characteristic FAS facial anomalies‡ - Yes - -
5. PAE (known or probable significant) and 1 facial anomaly‡ and growth deficit Yes Yes - -
6. PAE (known or probable significant) and 1 facial anomaly‡ and CNS deficit Yes Yes - -
7. PAE (known or probable significant) and CNS deficit - Yes - -
8. 1 facial anomaly‡ and growth deficit and CNS deficit - Yes Yes -
9. 1 facial anomaly‡ and growth deficit - - Yes -
10. 1 facial anomaly‡ and CNS deficit - - Yes -
11. Concern by parent or caregiver that their child might have FAS - - Yes -
CDC – United States Centers for Disease Control and Prevention criteria for referral for Fetal Alcohol Syndrome.
CNS – central nervous system.
PAE – prenatal alcohol exposure.
FAS – fetal alcohol syndrome.
†definitions of significant or high risk exposure vary between publications: CDC guidelines define significant as exposure to 7+ standard drinks per week, or 3 or
more drinks on multiple occasions, or both.
‡Characteristic FAS facial anomalies - smooth philtrum, thin vermillion border and small palpebral fissures.
‘-‘ not included.
*There is some overlap between criteria listed due to slight variations in content.
Watkins et al. BMC Pediatrics 2014, 14:178 Page 4 of 12
http://www.biomedcentral.com/1471-2431/14/178which consensus criteria for referral were developed;
however, all panel members participated in the review of
workshop outcomes and subsequent final recommenda-
tion development.
Process
The nominal group technique [32,33] was used to struc-
ture the group process, in combination with review of evi-
dence and open group discussion. Facilitated open group
discussion enabled consensus on referral criteria to be
achieved through the clarification, comparison and revi-
sion of proposed criteria for referral. Following the work-
shop a subgroup of the panel with specific expertise in
diagnosis reviewed the workshop outcomes and con-
firmed the criteria to be recommended. Field notes were
used to record the content of group discussions.
Analysis
Qualitative descriptive analysis [34] of participant contri-
butions in open discussion sessions, based on identifying
and categorising the underlying meaning of participant
contributions and statements [31], was used to describe
the main discussion content. All participants checked the
description of findings for consistency and accuracy. This
research adheres to the RATS guidelines for qualitative re-
search [35], and this study was approved by The University
of Western Australia Human Research Ethics Committee
and the Western Australian Aboriginal Health Information
and Ethics Committee.Results
Survey findings
Of the 139 individuals who were sent the survey, 103
(74%) returned a partially or fully completed survey, and
90 (65%) responded to 1 or more of the statements on re-
ferral criteria. Respondents to the statements on referral
criteria were paediatricians (42%), other medical practi-
tioners (26%) and other health professionals (32%), which
included allied health professionals, midwives, nurses,
health workers and health researchers. Almost three quar-
ters of respondents (74%) were female and most (92%)
were Australian. International respondents came from
New Zealand (4), the United Kingdom (1) and the United
States (2). Responses of the 7 international participants
did not differ substantially from those of the 83 Australian
participants, and due to the small number of inter-
national participants, findings are reported collectively.
Over three quarters of respondents (77%) reported ex-
perience in FASD screening or diagnosis.
Criteria for prenatal alcohol exposure
There was consensus agreement that referral for a diag-
nostic evaluation should occur when there is evidence of
significant prenatal alcohol exposure, defined as at least
7 or more standard drinks (defined as containing 10 g of
alcohol [36]) per week with 3 or 4 drinks on any one oc-
casion, or consumption of 5 or more drinks on any one
occasion (Table 2: Q4 - Q6). Approximately 60% of re-
spondents agreed that 7 or more drinks per week, or less
Table 2 Statement ratings: criteria for conducting a full diagnostic evaluation
Statements N % Agree (IQD)
Prenatal alcohol exposure criteria: What level of alcohol exposure, at any time during pregnancy, would alone be
sufficient to indicate the need for a full diagnostic evaluation for FASD:
Q1. Less than 7 standard drinks per week, and no more than 2 standard drinks on any one day 80 37.5 (2)
Q2. Less than 7 standard drinks per week, and between 3 and 4 standard drinks on any one day 78 61.5 (1)
Q3. 7 or more standard drinks per week, and no more than 2 standard drinks on any one day 79 59.5 (2)
Q4. 7 or more standard drinks per week, and between 3 and 4 standard drinks on any one day 81 81.5 (1)1
Q5. Binge drinking (5 or more standard drinks per occasion) less than once per week 84 78.6 (1)1
Q6. Binge drinking (5 or more standard drinks per occasion) once or twice per week 83 84.3 (1)2
Q7. No level of prenatal alcohol exposure is alone sufficient to indicate the need for a full diagnostic evaluation for FASD 72 45.8 (3)
Other criteria: In the absence of other known causes, a full diagnostic evaluation for FASD is required when there
is evidence of:
Q8. Concern by a parent or foster parent that their child might have a FASD 88 88.6 (1)1
Q9. All 3 of the characteristic FAS facial anomalies (smooth philtrum, thin vermillion border, and small palpebral fissures) 83 95.2 (1)2
Q10. 2 of the characteristic FAS facial anomalies 78 76.9 (1)1
Q11. The characteristic pattern of FAS facial anomalies (number unspecified) 79 72.2 (2)2
Q12. 2 of the characteristic FAS facial anomalies, and a growth deficit or any CNS abnormality (structural, neurological
or functional)
80 93.8 (1)2
Q13. 2 of the characteristic FAS facial anomalies, and a growth deficit and any CNS abnormality 82 92.7 (1)2
Q14. 1 of the characteristic FAS facial anomalies, and a growth deficit or any CNS abnormality 81 67.9 (1)
Q15. 1 of the characteristic FAS facial anomalies, and a growth deficit and any CNS abnormality 81 85.2 (1)1
Q16. Known or probable prenatal alcohol exposure, and 1 of the characteristic FAS facial anomalies, and a growth deficit
or any CNS abnormality
83 92.8 (1)1
Q17. Known or probable prenatal alcohol exposure, and 1 of the characteristic FAS facial anomalies, and a growth deficit
and any CNS abnormality
82 96.3 (1)2
Q18. Growth deficit and any CNS abnormality 79 55.7 (1)
Q19. Known or probable prenatal alcohol exposure, and growth deficit and any CNS abnormality 83 94.0 (1)2
Q20. Known or probable prenatal alcohol exposure, and any CNS abnormality 82 87.8 (1)1
Q21. 2 or more CNS abnormalities 73 43.8 (2)
Q22. Known or probable prenatal alcohol exposure, and 2 or more CNS abnormalities 82 95.1 (1)2
Q23. Known or probable prenatal alcohol exposure, and 1 or more birth defects 81 87.7 (1)1
Other statement about the use of the criteria:
Q24. A full diagnostic evaluation for FASD should occur outside standard criteria when health professionals have
concerns or doubts about FASD screening results
75 82.7 (1)
IQD: inter-quartile deviation.
Results for statements that reached consensus agreement (≥70% agree) are presented in bold.
1Statement defined minimum consensus criteria for referral at the 70% level of consensus.
2Statement did not define minimum consensus criteria for referral at the 70% level of consensus.
A standard drink is defined as containing 10 g of alcohol [36].
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day, indicate the need for diagnostic evaluation (Table 2:
Q2 and Q3).
Among the 29 survey participants who commented on
the referral criteria for prenatal alcohol exposure, 9 indi-
cated support for referral based on any level of confirmed
prenatal alcohol exposure. Reasons provided included: i) a
safe level of exposure has not been established, and it is
difficult to define the relevant level of exposure; and ii) the
use of a high level of exposure as a criterion for evaluationsends an inappropriate message to the public that lower
levels of exposure are safe.
‘… that is the only way that there will be a shift in
public opinion of the level of drinking that may “cause
a problem”…’
‘… teratogenicity has not been defined in terms of
amount of exposure or frequency of exposure, or even
timing of exposure. Certainly it may be appropriate to
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greater amounts or more frequent amounts of alcohol,
but this may miss a large amount of children who,
whilst they may not have FAS, will fall elsewhere on
the spectrum.’
Four respondents noted that detailed information on
exposure is often not available, the accuracy of reports
cannot be confirmed and many underreport consump-
tion due to fear or embarrassment.
‘It would be near impossible to gauge this level of
information from the clients I work with.’
‘The problem however is you will NEVER know when
the exposure pattern is being accurately recalled/
reported to you.’
In contrast, 7 respondents commented that evidence
of heavy alcohol use or a history of alcohol-related ill-
ness or dependency should be required to indicate the
need for diagnostic evaluation as well as assessment and
support for the mother. An additional five respondents
believed that heavy prenatal alcohol exposure is alone
not sufficient to warrant diagnostic evaluation due to
the limited diagnostic capacity in Australia and that re-
ferral should be based on the child’s difficulties.
‘Only higher levels of intake have consistent evidence
for harm. Additional concern needed before full
diagnostic work up of lesser exposures.’
‘Heavy alcohol [use] should prompt careful looking at
the child, but not diagnostic evaluation.’
‘… [prenatal alcohol exposure] alone is not enough to
warrant a full diagnostic evaluation. Living in an
Indigenous community this criteria would indicate
most of the children would need evaluations and there
just aren’t the resources available for that.’
Other criteria
Consensus agreement was reached on 13 of the 16 other
criteria for referral assessed, as well as when health pro-
fessionals had concerns or doubts about screening re-
sults (Table 2). Among the 14 participants who
commented on the other criteria for referral assessed,
general comments about the criteria for referral indi-
cated: support for sensitive criteria for referral to reduce
the risk of missing cases; that diagnostic evaluations for
FASD should not stand alone and are part of an inte-
grated assessment process for neurological or develop-
mental concerns; that the criteria for parental concern is
too non-specific; that the distinction between screening
and diagnosis is unclear; and that assessment is requiredto rule out other known causes of the criteria for refer-
ral, with FASD possibly a differential diagnosis.
‘… FASD can present in any of these combinations
because of its spectrum nature. All combinations
might therefore be of relevance, along with other
clinical context information needed to weigh them in
any particular case.’
‘… concerns by a carer are not sufficient on their own
to warrant a full diagnostic assessment. However, the
child should undergo screening.’Workshop recommendations
Workshop participants aimed to identify a small num-
ber of referral criteria that: can be applied in the case of
both known and unknown prenatal alcohol exposure;
have a specificity comparable with previously published
criteria; and exclude criteria which are not consistent
with the diagnostic categories recommended for use in
Australia (FAS, partial FAS (PFAS) and neurodevelop-
mental disorder-alcohol exposed (ND-AE) [21]).
Referral criteria endorsed by survey respondents at the
70% consensus level were less specific in some aspects
than criteria included in published guidelines, including
agreement with referral based on a ‘characteristic pattern
of FAS facial anomalies (number unspecified)’. Work-
shop participants recommended the use of more specific
criteria for referral based on facial anomalies, and that
parental or caregiver concern should prompt assessment
against the criteria for referral and monitoring of growth
and development if referral is not indicated at that time.
Five independent criteria for referral were recommended
(Table 3), with referral considered appropriate if individuals
satisfied any one of the five criteria. The inclusion of a cri-
terion for referral based on confirmed prenatal alcohol ex-
posure alone was most contentious, with strong debate
among panel members about the ability to identify and as-
sess an appropriate level of prenatal alcohol exposure suffi-
cient to warrant referral. The absence of evidence for a
minimum safe level of exposure to alcohol during preg-
nancy [37,38] was contrasted with strong evidence linking
adverse outcomes with moderate or high-level exposure
[39-42]. It was noted that the factors that mediate prenatal
alcohol-related harm are not fully understood, and factors
that influence the ability to report relevant exposure and
the existing capacity for service delivery must be consid-
ered in the development of criteria for referral. Panel
members agreed that referral based on prenatal alcohol
exposure alone should be limited to confirmed moder-
ate or high level exposure, similar to criteria in the Can-
adian and CDC guidelines and consistent with the
survey findings.
Table 3 Recommended Australian criteria for referral and their correspondence with published criteria
Recommended Australian criteria for referral Equivalent Criteria
Chudley [12] Loock [29] CDC [14] Astley [15]
1. Confirmed significant† prenatal alcohol exposure Yes Yes Yes -
2. 3 Characteristic FAS facial anomalies‡ Yes -# Yes Yes
3. 1 Facial anomaly‡ and growth deficit and 1 or more CNS abnormalities - Yes Yes -
4. Microcephaly and any confirmed prenatal alcohol exposure - Yes* - -
5. 2 or more CNS abnormalities and any confirmed prenatal alcohol exposure - Yes* - -
CDC – United States Centers for Disease Control and Prevention criteria for referral for Fetal Alcohol Syndrome.
CNS – central nervous system.
†significant exposure was defined as exposure to: 7+ standard drinks per week, or 5+ standard drinks on any one occasion.
‡Characteristic FAS facial anomalies - smooth philtrum, thin vermillion border and small palpebral fissures.
#guideline also requires evidence of significant prenatal exposure to alcohol.
*equivalent original criteria includes CNS deficits and known or probable significant PAE [29].
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quire the presence of confirmed prenatal alcohol expos-
ure (Table 3, criteria 2 and 3), and which were intended
to facilitate the referral of individuals who may have
FAS. Despite initial support for referral based on the
presence of two characteristic FAS facial anomalies
alone, which diverges from criteria included in all other
guidelines, participants ultimately agreed to recommend
referral based on the presence of all three characteristic
FAS facial anomalies. The simultaneous presence of all
three facial anomalies is specific to prenatal alcohol ex-
posure [16-18], and provides a mechanism for referral
in the absence of information on prenatal alcohol ex-
posure. Panel members noted that relaxation of the cri-
teria for facial anomalies has been associated with lack
of specificity for prenatal alcohol exposure and CNS
dysfunction [43].
The potential unreliability of palpebral fissure length
measurement by inexperienced assessors was a consider-
ation in criteria development. However, given the inclu-
sion of alternative criteria for referral for individuals
with unknown prenatal alcohol exposure, the need to as-
sess all three facial anomalies was anticipated to be in-
frequent. These alternative criteria, which were endorsed
by survey respondents (Table 2 Q14 and Q18) and work-
shop participants, require the presence of a single facial
anomaly, growth deficit at any time, and CNS abnormal-
ity. This need for evidence of abnormality in three core
areas in the absence of information on prenatal alcohol
exposure is present in both the CDC guidelines for FAS
[14] and the Canadian guidelines for FASD [29] (Table 3).
The two final recommended criteria for referral provide
a mechanism for the referral of individuals with possible
ND-AE based on evidence of any confirmed prenatal
alcohol exposure in conjunction with significant CNS
abnormalities. Panel members noted the significance of
microcephaly among individuals with FASD [44], with a
prevalence of 45% among individuals with diagnosed FAS
and PFAS, and 25% among individuals diagnosed withstatic encephalopathy-alcohol exposed using University of
Washington criteria [15].
Evaluation of the consensus referral criteria was recom-
mended to ensure that the criteria can effectively identify
individuals at high risk of FASD. Guidelines and training
resources for health professionals to support the imple-
mentation of these criteria, and resources for individuals
referred for diagnosis, were also recommended.
Assessment methods
Panel members recommended assessment in the follow-
ing four main areas.
Prenatal alcohol exposure
A detailed history of alcohol consumption during preg-
nancy is not always available. Information from medical
or other official records, or from a reliable witness, may
be required to establish direct evidence of confirmed
prenatal alcohol exposure or alcohol dependency during
the index pregnancy. Where an exposure history can be
obtained, assessment of the level of known prenatal alco-
hol exposure should include the Alcohol Use Disorders
Identification Test-Consumption (AUDIT-C) questions
[45] consistent with nationally recommended assessment
methods [46]. The context and timing of exposure to alco-
hol and other potentially teratogenic substances during
pregnancy should also be assessed, including exposure
prior to confirmation of pregnancy. Assessment at birth
should include signs of alcohol withdrawal in the mother
and neonate.
Characteristic FAS facial anomalies
Assessment of facial anomalies is not required in all re-
ferral scenarios; however, it has particular significance
where prenatal alcohol exposure is unknown (Figure 1).
Assessment for the thin vermillion border and smooth
philtrum characteristics of FAS should be conducted using
the appropriate University of Washington Lip-Philtrum
Guide [47]. Ranks 4 and 5 are considered consistent with
1. Determine level of known 
prenatal alcohol exposure 
Confirmed significant exposure Any confirmed exposure Unknown exposure
Refer for specialist assessment 
i. Microcephaly or 
ii. 2 or more CNS deficits
i. 3 facial anomalies, or 
ii. 1 facial anomaly and growth 
deficit and CNS deficit 
Assessment process Criteria for referral 
2. Assess other required 
referral criteria
3. Refer if criteria are met
†
Yes Yes Yes
Yes Yes
No
Figure 1 Summary of recommended 3-step referral assessment process and criteria for individuals who may have fetal alcohol
spectrum disorder. †If other required criteria for any confirmed exposure are negative, assess criteria for unknown exposure CNS – central
nervous system.
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should be performed by trained and experienced assessors
as described in the University of Washington 4-Digit
Diagnostic Code [47], because physical measurements of
palpebral fissure length by inexperienced assessors may be
unreliable. Where clinicians experienced in this assess-
ment are unavailable, accurate assessment of all character-
istic FAS facial anomalies may be performed using facial
photographic screening [17], which could be reviewed by
experts locally or remotely by an external service.Growth
Assessment for growth deficit at any time that is unex-
plained by other causes should be performed using stand-
ard objective anthropometric methods and compared with
locally appropriate population references for age and gen-
der, such as the CDC growth charts [48]. Standard proto-
cols should be used to correct for gestational age if
required and parental heights if available.Central nervous system (CNS) abnormalities
Non-diagnostic indicators of CNS abnormality may be
identified during the physical examination; through object-
ive assessments of CNS structure or function, including
the results of investigations or scans; from the results of
valid and reliable behavioural and developmental screening
tools, such as the Strengths and Difficulties Questionnaire
[49] or from reports by parents, carers or other credible
sources. A range of valid and reliable developmental and
behavioural screening tools routinely used by health pro-
fessionals in Australia could be used to indicate the need
for referral. Different screening tests may be required for
different age groups and settings. Assessment of CNS
abnormalities should include measurement of headcircumference and comparison with appropriate popu-
lation references.
Discussion
There is currently no international consensus on referral
criteria for individuals with specific presentations suggest-
ive of FASD for specialist diagnostic evaluation, and there
is little published empirical evidence to guide recommen-
dation development or the design of other strategies to
improve recognition of these disorders. Consultation with
health professionals and a consensus development work-
shop were used to review published criteria for referral
and adapt these for the Australian context. Consistent
with existing criteria for referral, we found that survey
and workshop participants supported the use of indica-
tors linked to both aetiological and diagnostic factors.
Four of the five consensus criteria are similar to published
Canadian criteria [29], and three include elements repre-
sented in the CDC guidelines for the diagnosis of FAS [14].
There is a recognised need for distinction between
screening and diagnostic assessments for FASD. How-
ever, there is little specific information available about
how recommended criteria for referral should be imple-
mented. The proposed consensus referral criteria provide a
well-defined conceptual framework for assessment which
is distinct from that used to guide diagnostic assessment,
despite the use of diagnostic assessment tools for growth,
facial anomalies and CNS abnormalities where required.
Specification of the conceptual basis for application of each
referral criterion (Figure 1) enables health professionals to
identify the minimum extent of assessment required to ful-
fil the recommended referral criteria. Depending on the
degree of information available on prenatal alcohol expos-
ure, completion of assessments for all four domains may
not be required. This may be of particular value for
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aspect of facial anomaly assessment. Individuals meeting
the criteria for referral should undergo comprehensive as-
sessment by a relevant specialist medical practitioner using
a multidisciplinary assessment approach [21].
The five consensus criteria for referral are based on a
2-stage assessment process which involves assessment of
prenatal alcohol exposure and identification of additional
indicators when prenatal alcohol exposure in the high
risk range is not confirmed. This approach in part allows
for the ability of parents or caregivers to report exposures.
With the intent of maintaining specificity, evidence of
other abnormalities associated with prenatal alcohol ex-
posure is required for referral where there is no evidence
of prenatal exposure to alcohol in the high risk range. The
presence of all three facial anomalies has particular signifi-
cance as a sensitive and specific indicator of prenatal alco-
hol exposure [16-18], and assessment is only required in
the case of unknown prenatal alcohol exposure. A range
of evidence may be used in the referral context to estab-
lish the presence of CNS abnormality. A comprehensive
assessment of CNS function may be utilised if available,
but is not required prior to the diagnostic assessment.
Evidence of prenatal alcohol exposure is the most con-
sistently used indicator of the need for referral for spe-
cialist assessment among published criteria, although
there is some variation in the definition of this criterion.
The agreed minimum level of exposure that alone indi-
cates the need for specialist assessment correlates well
with the CDC criteria for referral [14], ‘significant expos-
ure at a level associated with physical or developmental
effects’ described in the Canadian guidelines [12], and
evidence on the potential importance of moderate levels
of prenatal alcohol exposure to fetal behavioural out-
comes [50]. Less than 40% of survey participants agreed
that individuals who were exposed to less than 7 stand-
ard drinks per week and no more than 2 drinks on any
one occasion should undergo specialist assessment in
the absence of other indicators.
The consensus criterion for high risk exposure is more
conservative than the criterion of any confirmed prenatal
alcohol exposure used in the Washington State program
[15]. Although the decision was not unanimous, panel
members reached consensus that any confirmed prenatal
alcohol exposure alone as an indicator for referral was too
nonspecific, and that any prenatal exposure should only
indicate the need for referral in combination with evi-
dence of CNS abnormalities. Evaluation of referrals for
the Washington State diagnostic clinics supports the val-
idity of the use of any prenatal alcohol exposure as an
indicator of FASD risk [15]. However, research indicates
that most individuals assessed were exposed to high levels
of prenatal alcohol exposure or had an alcohol use dis-
order [15], and factors that influence the implementationof this criterion, including whether the presence of other
features influence the decision to refer, have not been de-
scribed. The levels of exposure considered to be associated
with a high risk of FASD will require review as further evi-
dence on the effects of lower level exposures becomes
available, as noted in other guidelines [12,14,47].
We found agreement that the presence of all three char-
acteristic FAS facial anomalies is an important indicator of
the need for a referral in the absence of confirmed pre-
natal alcohol exposure, consistent with existing recom-
mendations [12,14,15]. Referral based on the presence of
all three facial anomalies primarily targets individuals with
FAS and who have unknown prenatal alcohol exposure.
These presentations are likely to be only a small propor-
tion of eligible cases [5], and FAS is the only disorder that
can be diagnosed in the absence of information on pre-
natal alcohol exposure due to the specificity of the three
characteristic FAS facial anomalies. Although there is evi-
dence of a correlation between the presence of character-
istic FAS facial anomalies, prenatal alcohol exposure and
brain dysfunction [18] which suggests that partial expres-
sions of the FAS facial phenotype may be important risk
factors for brain damage associated with prenatal alcohol
exposure [51,52], there is insufficient evidence to justify
relaxation of this referral criterion at this time.
Further research is required to optimise these consensus
referral criteria and recommended assessment processes
based on the evaluation of their feasibility, acceptability
and effectiveness. The implementation of referral criteria
must recognise the challenges and limitations for clini-
cians who have little expertise in the assessment of facial
anomalies and those who work in regional and remote lo-
cations. Concerns about the use of facial dysmorphology
assessment outside the diagnostic context, the potential
unreliability of formal assessment of palpebral fissure
length among inexperienced assessors, and the suitability
of existing norms for the Australian population require
investigation. The establishment of a centralised facial
photographic analysis service to enable specialist assess-
ment of facial anomalies using locally captured digital
images may provide a feasible and accurate method to
support health professionals evaluate the need for refer-
ral. Ultimately our recommended referral criteria aim to
inform the health professionals’ clinical decision mak-
ing, and uncertainty about assessment findings can also
provide the basis for specialist referral based on health
professional concern.
Although only 77% of respondents reported experience
in FASD screening or diagnosis, expertise relevant to the
development of criteria for referral is not confined to indi-
viduals with practical experience in screening or diagnosis,
and includes individuals who have non-clinical roles. The
established under-recognition of FASD in Australia [3] is
also consistent with Australian health professionals’
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mately 70% or more of survey respondents completed the
questions on referral criteria, suggesting that most be-
lieved they had expertise relevant to the development of
criteria for referral. Overall response to the survey was
lowest among participants who were passively recruited
through the APSU. Although the survey response
exceeded the 70% recommended level [53] and is compar-
able to that reported among similar Delphi studies of
health professionals [54,55], non-response may have influ-
enced the survey findings.
The lack of empirical evidence relevant to the devel-
opment of recommended Australian criteria for referral
was also a limitation of this study. Recommended cri-
teria were developed by adapting criteria included in
published guidelines based on input from health profes-
sionals and review within a formal consensus develop-
ment framework. Although not all panel members were
able to attend the 2-day face-to-face consensus develop-
ment workshop, all panel members were engaged in
reviewing evidence and outputs prior to and following
the workshop and in formulating the final recommenda-
tions. An understanding of the appropriateness, feasibil-
ity and performance of these criteria in the Australian
context, including evaluation of their predictive value and
cost-effectiveness is now required. Examination of the ap-
propriateness of existing population reference data in cul-
turally diverse populations in Australia is also needed. The
successful implementation of referral criteria will also de-
pend upon the ability of services providers who do not
have specific expertise in FASD to recognise the issue, be
aware of the specialist services available for diagnosis and
management, and of the potential benefits of referral.
Conclusion
We have established the basis for nationally applicable cri-
teria for referral in Australia. Further work is required to
evaluate the appropriateness and effectiveness of the cri-
teria for referral, and develop resources to facilitate imple-
mentation of standard referral practices, including training
and support for health professionals and information for
individuals who are undergoing diagnosis and their par-
ents or carers. These processes will support the incorpor-
ation of standard criteria for referral into cost effective
strategies to improve the ability of health professionals to
identify and prevent FASD. Establishing effective mecha-
nisms for referral is critical to improving the capacity for,
and access to, FASD diagnosis in Australia.
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